

KIDNEY WEEK 2020 REIMAGINED

Don't miss this opportunity to view our Virtual Exhibitor Spotlight on demand!

MINIMIZE RISK OF IRON OVERLOAD: Centralize Delivery With a Novel Approach to Anemia Management in Hemodialysis

Log on to join a panel of experts who will discuss the current targets for anemia management and the place in therapy for TRIFERIC® (ferric pyrophosphate citrate). The experts will share their real-world clinical experience with this novel physiologic approach to iron maintenance.

VIDEO PRESENTATION

Available for viewing on the ASN Kidney Week 2020 Reimagined website
from **October 22–December 4, 2020**

EXPERT PANEL



Marcos Rothstein, MD
Professor of Medicine
Washington University
School of Medicine
St. Louis, Missouri



Michael J. Germain, MD
Nephrologist
Baystate Medical Center
Springfield, Massachusetts



Erica Lawless, MSN
Clinic Manager
American Renal Associates
Holyoke, Massachusetts

HOW TO ACCESS

Click the “Exhibits & Spotlight” tile on the Home page to locate the presentation.

The intended audience for this program is healthcare professionals involved in the management of patients with hemodialysis-dependent chronic kidney disease. This program is sponsored by Rockwell Medical, Inc.
The Exhibitor Spotlight is not a Continuing Education (CE) activity.

INDICATION

TRIFERIC is indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD).

Limitations of Use

- TRIFERIC is not intended for use in patients receiving peritoneal dialysis.
- TRIFERIC has not been studied in patients receiving home hemodialysis.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving parenteral iron products. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after hemodialysis until clinically stable. Personnel and therapies should be immediately available for the treatment of serious hypersensitivity reactions. Hypersensitivity reactions have been reported in 1 (0.3%) of 292 patients receiving TRIFERIC in two randomized clinical trials.

Iron status should be determined on pre-dialysis blood samples. Post dialysis serum iron parameters may overestimate serum iron and transferrin saturation.

Adverse Reactions

Most common adverse reactions (incidence $\geq 3\%$ and at least 1% greater than placebo) in controlled clinical studies include: headache, peripheral edema, asthenia, AV fistula thrombosis, urinary tract infection, AV fistula site hemorrhage, pyrexia, fatigue, procedural hypotension, muscle spasms, pain in extremity, back pain, and dyspnea.

[Please click here to See Full Prescribing Information for TRIFERIC.](#)

Visit www.TRIFERIC.com for more information.

If you would like to contact us directly or have an adverse event to report, please contact Rockwell Medical at 800-449-3353.

Presented by:



[Terms of Use](#) [Privacy Policy](#)
Rockwell Medical | 30142 Wixom Road | Wixom, MI 48393 USA
TRIFERIC® is a registered trademark of Rockwell Medical, Inc.
© 2020 Rockwell Medical, Inc. All rights reserved.
US-TF-20-HCP-00057 09/2020

